Table 1.
Clinicopathological characteristics of glioma patients in TCGA, CCGA, and WCH cohort.
| Glioma Patients | TCGA cohort | CGGA cohort | WCH cohort |
|---|---|---|---|
| Sample size | 666 | 229 | 78 |
| Normal Brain | 5 | - | 16 |
| Age | 46 (14-89) | 43 (10-79) | 46 (14-77) |
| Sex | |||
| Female | 282 | 87 | 31 |
| Male | 382 | 142 | 47 |
| NA | 2 | 0 | 0 |
| Histology | |||
| Astrocytoma | 343 | 84 | 22 |
| Oligodendroglioma | 168 | 60 | 21 |
| Glioblastoma | 155 | 85 | 35 |
| WHO Grade | |||
| G2 | 216 | 94 | 29 |
| G3 | 237 | 50 | 14 |
| G4 | 155 | 85 | 35 |
| NA | 58 | 0 | 0 |
| IDH mutation status | |||
| Mutant | 424 | 116 | 42 |
| WT | 237 | 112 | 36 |
| NA | 5 | 1 | 0 |
| 1p19q codeletion status | |||
| Codel | 168 | 54 | 19 |
| Non-codeletion | 491 | 172 | 44 |
| NA | 7 | 3 | 15 |
| TERT promoter mutation status | - | ||
| Mutant | 341 | - | 30 |
| WT | 157 | - | 24 |
| NA | 168 | - | 24 |
| MGMT promoter methylation status | |||
| Methylated | 473 | 99 | 36 |
| Unmethylated | 160 | 116 | 13 |
| NA | 33 | 14 | 29 |
| ATRX mutation status | - | ||
| Mutant | 194 | - | 23 |
| WT | 461 | - | 53 |
| NA | 11 | - | 2 |
TCGA, The cancer Genome Atlas; CGGA, Chinese Glioma Genome Atlas; WCH, West China Hospital; WHO, World Health Organization; IDH, isocitrate dehydrogenase; TERT, telomerase reverse transcription; MGMT, O6-methylguanine-DNA methyltransferase; ATRX, alpha thalassemia/mental retardation syndrome X-Linked protein/gene; WT, wild; NA, not available.